Nurix Therapeutics (NRIX) vs SELLAS Life Sciences Group (SLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Nurix Therapeutics (NRIX) over the past year, gaining 495.3% versus a gain of 131.2%. Over five years, SLS leads with a +28.1% price change compared with -21.2% for NRIX. Nurix Therapeutics is the larger company by market cap ($2.36 billion vs $2.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | SLS |
|---|---|---|
| Share price | $22.73 | $11.31 |
| Market cap | $2.36B | $2.28B |
| 1-day change | +0.58% | -0.26% |
| YTD return | +19.82% | +200.00% |
| 1-year return | +131.23% | +495.26% |
| 5-year return | -21.16% | +28.09% |
| EPS (TTM) | $-3.46 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.23 | $15.88 |
| 52-week low | $9.00 | $1.39 |
| Distance from 52-week high | -19.48% | -28.78% |
| Analyst consensus | none | none |
| Avg. price target upside | +49.27% | +187.36% |
| Average volume | 1.27M | 6.75M |
| Shares outstanding | 103.78M | 201.95M |
| Employees | 317 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed NRIX by 364.0 percentage points over the past year.
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
NRIX vs SLS FAQ
Which is bigger, Nurix Therapeutics or SELLAS Life Sciences Group?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.36B compared with $2.28B for SELLAS Life Sciences Group (SLS).
Which stock has performed better over the past year, NRIX or SLS?
SLS returned +495.26% over the past 12 months, compared with +131.23% for NRIX (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and SELLAS Life Sciences Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.